2025 年第 5 期 第 20 卷

外用红色诺卡氏菌细胞壁骨架治疗宫颈高危型人乳头瘤病毒持续感染患者的效果研究

Efficacy of Nocardia rubra cell wall skeleton in the treatment of female patients with persistent cervical high-risk human papillomavirus infection

作者：贾红星1王克芳2

英文作者：Jia Hongxing1 Wang Kefang2

单位：1河北北方学院，张家口075000；2首都医科大学附属北京安贞医院妇产科，北京100029

英文单位：1Hebei North University Zhangjiakou 075000 China; 2Department of Obstetrics and Gynaecology Beijing Anzhen Hospital Capital Medical University Beijing 100029 China

关键词：高危型人乳头瘤病毒感染；红色诺卡氏菌细胞壁骨架

英文关键词：High-riskhumanpapillomavirusinfection;Nocardiarubrumcellwallskeleton

• 摘要：

• 目的 探讨外用红色诺卡氏菌细胞壁骨架（Nr-CWS）治疗宫颈高危型人乳头瘤病毒（HR-HPV）持续感染患者的临床效果。方法 收集2021年1月至2023年8月于首都医科大学附属北京安贞医院妇科门诊就诊的女性宫颈HR-HPV持续感染（≥1年）患者120例，搜集患者临床资料进行回顾性分析。根据患者意愿选择的治疗方式分为观察组和对照组，各60例。对照组给予生活方式干预，包括健康的生活方式、适当锻炼身体、增强机体免疫力；观察组在生活方式干预基础上采用Nr-CWS外敷子宫颈治疗，10 次为1个疗程。治疗结束后6、12个月分别评估2组疗效。结果 治疗后6、12个月，观察组总有效率均明显高于对照组［63.3%（38/60）比18.3%（11/60）、73.3%（44/60）比35.0%（21/60）］，差异均有统计学意义（均P＜0.05）。观察组治疗后6、12个月不同HPV亚型患者疗效（总有效率）比较，差异均无统计学意义（均P＞0.05）。结论 外用Nr-CWS治疗女性宫颈HR-HPV持续感染效果显著。

• Objective To investigate the clinical effect of Nocardia rubrum cell wall skeleton (Nr-CWS) topical treatment on women with cervical high-risk human papillomavirus (HR-HPV) persistent infection. Methods A total of 120 female patients with persistent cervical HR-HPV infection (≥1 year) who visited the gynecological clinic of Beijing Anzhen Hospital, Capital Medical University from January 2021 to August 2023 were collected, and the clinical data of the patients were collected for retrospective analysis. According to the patients′ preferred treatment method, they were divided into observation group and control group, with 60 cases in each group. The control group was given lifestyle intervention, including healthy lifestyle, appropriate exercise, enhance body resistance; the patients in the observation group were treated with external application of Nr-CWS on the basis of immunity intervention, 10 times as a course of treatment. The efficacy of the two groups was evaluated at 6 and 12 months after treatment. Results At 6 and 12 months after treatment, the total effective rate of the observation group was significantly higher than that of the control group ［63.3%（38/60） vs 18.3%（11/60）, 73.3%（44/60） vs 35.0%（21/60）］(all P＜0.05). There was no statistically significant difference in the efficacy (total effective rate) of different subtypes of persistent HR-HPV patients in the observation group at 6 and 12 months after treatment (all P＞0.05). Conclusion Topical Nr-CWS is effective in the treatment of persistent cervical HR-HPV infection in women.